SGLT2 Inhibitor Intermediate V Fluorination via Catalytic Mediator

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The existing synthesis method for SGLT2 inhibitor intermediate V suffers from low yield and high impurity content, particularly during the fluorination process, due to the production of a monofluoro-impurity, making it challenging to ensure the safety and quality of the final product.

Innovation Solution

A modified preparation method involving a substitution reaction with a fluorination reagent in the presence of a catalytic reagent and solvent, such as diethylaminosulfur trifluoride and anhydrous ethanol, under controlled temperature and time conditions, significantly reduces impurity production and improves yield.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If fluorination reagent is used to fluorinate carbonyl group, then fluorinated product is obtained, but monofluoro-impurity is easily produced with high content

Engineering Contradiction:
Improvepurity of fluorinated productVSAvoidmonofluoro-impurity content
Core Design Contradiction:
Manufacturing precisionVSObject-generated harmful factors

Solution Approach 1:

A catalytic reagent is introduced as an intermediary substance to mediate the fluorination reaction between the fluorination reagent and the carbonyl group. This catalytic reagent facilitates the formation of the desired difluoro product while suppressing the formation of monofluoro-impurity, resolving the contradiction between obtaining fluorinated product and avoiding harmful impurities.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The reaction conditions are optimized by changing parameters such as temperature, catalyst concentration, and reagent ratios. By controlling these parameters, the reaction selectively produces the desired fluorinated product with high purity while minimizing monofluoro-impurity formation, thus resolving the contradiction between product obtention and impurity generation.

Inventive Principle:
Principle #35Parameter changes

2Productivity

If conventional fluorination method is used, then synthesis is completed, but yield is low and conversion rate is poor

Engineering Contradiction:
Improveyield of intermediate VVSAvoidconversion rate of fluorination
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The catalytic reagent acts as a mediator that enhances the reaction efficiency between the fluorination reagent and carbonyl group. This catalyst increases the conversion rate and improves the yield of intermediate V, simultaneously resolving the contradictions between productivity and reliability.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The catalytic reagent enables continuous and efficient fluorination reaction, maintaining high conversion rates throughout the reaction process. This continuous useful action ensures high yield and reliable conversion, addressing both productivity and reliability contradictions.

Inventive Principle:
Principle #20Continuity of useful action

3Manufacturing precision

If multiple purification processes are implemented, then impurity content is reduced, but production complexity and time increase

Engineering Contradiction:
Improvepurity of intermediate VVSAvoidnumber of purification processes
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The catalytic reagent performs preliminary anti-action by preventing the formation of monofluoro-impurity during the fluorination reaction itself. This preventive approach eliminates the need for multiple subsequent purification processes, resolving the contradiction between achieving high purity and reducing process complexity.

Inventive Principle:
Principle #9Preliminary anti-action

Solution Approach 2:

Instead of treating impurities after formation, the catalytic reagent converts the potential harmful effect of impurity formation into a beneficial selective reaction pathway. This approach achieves high purity directly during synthesis, eliminating the need for complex purification processes.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method enhances the purity and yield of the SGLT2 inhibitor intermediate V, simplifies the purification process, and ensures safer industrial production while reducing the content of the monofluoro-impurity, making it suitable for pharmaceutical applications.

Implementation Method 1

subjecting a compound of Formula IV to a substitution reaction with a fluorination reagent

Methodology Applied
Scientific EffectSubstitution reaction: Chemical Bonding

Implementation Method 2

in the presence of a catalytic reagent, carrying out heat-preservation substitution reaction with a fluorination reagent

Methodology Applied
Scientific EffectCatalysis: Catalysis

Data Source

PatentUS20250091975A1Preparation method for SGLT2 inhibitor intermediate v
Publication Date: 2025.03.20 JIANGSU WANBANG BIOPHARMLS
  • US20250091975A1 patent drawing
  • US20250091975A1 patent drawing
  • US20250091975A1 patent drawing

AI summary

Disclosed is a preparation method for an SGLT2 inhibitor intermediate V, the method comprising: adding a compound IV to a solvent, and in the presence of a catalytic reagent, carrying out heat preservation reaction with a fluorination reagent. The preparation process for the intermediate V is simple in operations, mild in reaction conditions and high in safety, facilitates quality control and is suitable for industrial production. In addition, the intermediate V prepared by the method is high in purity, has few side reaction product monofluoro-impurity shown as structural Formula V′, is easy to purify, and is applicable to quality research on active pharmaceutical ingredients and preparations of the SGLT2 inhibitor.